This is an early access version, the complete PDF, HTML, and XML versions will be available soon.
Open AccessArticle
Enrofloxacin Pharmaceutical Formulations through the Polymer-Free Electrospinning of β-Cyclodextrin–oligolactide Derivatives
by
Diana-Andreea Blaj
Diana-Andreea Blaj 1,2
,
Cătălina Anișoara Peptu
Cătălina Anișoara Peptu 2,
Maricel Danu
Maricel Danu 2,
Valeria Harabagiu
Valeria Harabagiu 1
,
Cristian Peptu
Cristian Peptu 1,*
,
Alexandra Bujor
Alexandra Bujor 3,
Lăcrămioara Ochiuz
Lăcrămioara Ochiuz 3,*
and
Cristina Gabriela Tuchiluș
Cristina Gabriela Tuchiluș 4
1
“Petru Poni” Institute of Macromolecular Chemistry, 700487 Iasi, Romania
2
Faculty of Chemical Engineering and Protection of the Environment, “Gheorghe Asachi” Technical University of Iasi, 700050 Iasi, Romania
3
Faculty of Pharmacy, “Grigore. T. Popa” University of Medicine and Pharmacy, 700115 Iasi, Romania
4
Faculty of Medicine, “Grigore. T. Popa” University of Medicine and Pharmacy, 700115 Iasi, Romania
*
Authors to whom correspondence should be addressed.
Pharmaceutics 2024, 16(7), 903; https://doi.org/10.3390/pharmaceutics16070903 (registering DOI)
Submission received: 31 May 2024
/
Revised: 28 June 2024
/
Accepted: 4 July 2024
/
Published: 5 July 2024
Abstract
Enrofloxacin (ENR), a member of the fluoroquinolone class of antibiotics, is widely used in veterinary medicine to treat bacterial infections. Like many antibiotics, ENR has limited water solubility and low bioavailability. To address these challenges, drug formulations using solid dispersions, nanosuspensions, surfactants, cocrystal/salt formation, and inclusion complexes with cyclodextrins may be employed. The approach described herein proposes the development of ENR formulations by co-electrospinning ENR with custom-prepared cyclodextrin–oligolactide (CDLA) derivatives. This method benefits from the high solubility of these derivatives, enabling polymer-free electrospinning. The electrospinning parameters were optimized to incorporate significant amounts of ENR into the CDLA nanofibrous webs, reaching up to 15.6% by weight. The obtained formulations were characterized by FTIR and NMR spectroscopy methods and evaluated for their antibacterial activity against Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa. This study indicates that the presence of CDLA derivative does not inhibit the antibacterial activity of ENR, recommending these formulations for further development.
Share and Cite
MDPI and ACS Style
Blaj, D.-A.; Peptu, C.A.; Danu, M.; Harabagiu, V.; Peptu, C.; Bujor, A.; Ochiuz, L.; Tuchiluș, C.G.
Enrofloxacin Pharmaceutical Formulations through the Polymer-Free Electrospinning of β-Cyclodextrin–oligolactide Derivatives. Pharmaceutics 2024, 16, 903.
https://doi.org/10.3390/pharmaceutics16070903
AMA Style
Blaj D-A, Peptu CA, Danu M, Harabagiu V, Peptu C, Bujor A, Ochiuz L, Tuchiluș CG.
Enrofloxacin Pharmaceutical Formulations through the Polymer-Free Electrospinning of β-Cyclodextrin–oligolactide Derivatives. Pharmaceutics. 2024; 16(7):903.
https://doi.org/10.3390/pharmaceutics16070903
Chicago/Turabian Style
Blaj, Diana-Andreea, Cătălina Anișoara Peptu, Maricel Danu, Valeria Harabagiu, Cristian Peptu, Alexandra Bujor, Lăcrămioara Ochiuz, and Cristina Gabriela Tuchiluș.
2024. "Enrofloxacin Pharmaceutical Formulations through the Polymer-Free Electrospinning of β-Cyclodextrin–oligolactide Derivatives" Pharmaceutics 16, no. 7: 903.
https://doi.org/10.3390/pharmaceutics16070903
Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details
here.
Article Metrics
Article Access Statistics
For more information on the journal statistics, click
here.
Multiple requests from the same IP address are counted as one view.